Biofrontera AG (FRA:B8FK)

Germany · Delayed Price · Currency is EUR

2.930

-0.070 (-2.33%)

Last updated: Oct 23, 2026, 8:00 AM CEST

Market Cap	18.96M +19.1%
Revenue (ttm)	15.97M +42.1%
Net Income	5.26M
EPS	0.86
Shares Out	n/a
PE Ratio	3.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Open	2.930
Previous Close	3.000
Day's Range	2.930 - 2.930
52-Week Range	2.180 - 4.800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic produ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1997

Employees 62

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol B8FK

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -3.97 million, -8.85% less than in 2024.

Financial Statements